Zelluna | Sustainability Performance
Ultimovacs ASA develops immunotherapy treatments aimed at providing solutions for cancer patients through innovative therapeutic approaches and clinical research.
1980
Norway
1,001 - 5,000 employees
Biotechnology
$500K - 1M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#4963
Overall#119
in Norway#68
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Environmental
Energy consumption
Renewable energy
Laggard
Renewable electricity
Reveal data for 1 credit
80%2023
Industry rank: 10 out of 251
Total electricity consumption
and % renewables
(MWh, % of consumption)
Industry rank: 10 out of 251
Total electricity
Share of renewable electricity
Industry benchmark
Controversy level
- Zelluna was a pre-revenue clinical-stage company with significant R&D costs and going-concern financing risks.
